Connecting Pre-Series C Companies With The Right Healthcare Investors

Skip the 3-5 months of networking and fundraising headaches.
Connect with perfectly aligned institutional investors in ticket size and interests within 21 days.
Raise your round in the shortest amount of time possible.

To deliver superior results, we onboard maximum 8 partners per quarter.

Who We Work With?

Biotech

Drug Discovery, Genetic Research, Biopharmaceuticals, Vaccine Development, Regenerative Medicine.

Medtech

Medical Devices, Diagnostic Equipment, Wearable Health Tech, Surgical Instruments, Robotic Surgery.

Services

Hospitals, Specialty Clinics, Long-term Care Facilities, Telehealth Services, Home Healthcare.

Health IT

Electronic Health Records (EHRs), Health Information Exchanges (HIEs), Telemedicine Platforms, Mobile Health Applications, Clinical Decision Support Systems (CDSS).

Don't Take Our Word For It

"Raising funds for our digital health company has always been challenging, particularly getting in front of investors. This time, we partnered with Nam and his team at Apex Ascension, and the results have been outstanding. "
Dr Michael J. Gardner
Founder, National Scoliosis Clinic
"After three months with another firm and no VC meetings, we were frustrated by the misalignment in investor fit. Apex Ascension changed everything. In just more than a week, they secured 14 meetings with perfectly aligned investors in terms of ticket size and interest. "
Nandan Rao
CEO, Kannact Health & Starlight
"Apex Ascension has introduced us to a lot of investors, and they've done a great job for us."
Thomas Kinder
CEO, Subchondral Solutions

Our Team

Nam T. - Managing Director

Nam manages operations, messaging, and capital raising infrastructure. With a background in neuroscience and business, he has built a growth consulting firm that has generated over $55 million in attributable online revenue for healthcare and tech companies

Justin W. - Investment Lead

Justin leads portfolio sourcing, due diligence, financial modeling, and portfolio management. Formerly an Associate at Pathway Bioventures, he specialized in early-stage biotech investments and M&A structures, and is currently a Board Observer at Kiyatec and Functional Fluidics

Ryan B. - Outbound Lead

Ryan leads investor segmentation and outreach strategy. With extensive experience in securing 20+ meetings per month for B2B SaaS/Tech companies through multiple channels, he brings valuable expertise to our team.

PROCESS

Dive Deeper Into Our Healthcare Capital Raising Process

01 - Solving For Investor Segment
Using proprietary technology and extensive networks, we identify and segment investors based on investment stage, valuation, and industry specialization. This approach ensures a curated list of mandate-specific investors tailored to healthcare companies, including medtech, biotech, and health IT. Our precise targeting enhances outreach effectiveness and secures strong investor commitments.
02 - Solving For Presentation
In Phase 2, we develop and refine all marketing materials, including presentation decks and video presentations, to effectively communicate the value proposition to investors. We focus on concise messaging, visual aids, and storytelling techniques to enhance engagement and understanding. Utilizing online channels for distribution amplifies visibility and reach, ensuring that healthcare companies connect with the right investors.
03 - Solving Introductions
Phase 3 focuses on leveraging existing networks and strategic outreach to connect with potential investors. This includes private server email campaigns, personalized outreach, and content optimization. We also expand reach through LinkedIn campaigns and targeted outreach to ensure engagement with relevant investors, maximizing opportunities for successful connections.
04 - Solving For Conversions
Phase 4 emphasizes building on introductions by conducting pre-meeting due diligence on investors, assigning an analyst to introductory calls, and refining materials and communication based on prospect feedback and initial conversations. This ensures a tailored approach, maximizing the potential for successful engagement and progression toward investment agreements.
05 - Solving For Deal Closure
Phase 5 focuses on deal closure by establishing a comprehensive data room, minimizing hold-ups during due diligence, and expediting the overall process. Our attention to detail ensures completeness and accessibility of documentation, addressing investor concerns preemptively to facilitate a smooth and efficient closure.
Previous slide
Next slide

VERTICALS / 03

Investor Verticals We Work
With

Institutional Investors

These are sophisticated entities such as banks, insurance firms, and pension funds, characterized by their substantial capital base and rigorous investment protocols. Institutional investors prioritize stable, long-term returns and typically engage in diversified investment portfolios.

Accredited Retail Investors

Accredited retail investors are individuals who meet stringent financial criteria outlined by regulatory bodies. They possess the financial capacity to participate in private investment opportunities not accessible to the general public. Accredited retail investors pursue higher-yield prospects, often embracing a heightened risk tolerance.

High Net Worth Individuals (HNWI)/Angels

HNWIs, distinguished by their considerable wealth, actively engage in direct investments, particularly in nascent ventures, as angel investors. Apart from financial backing, they offer valuable expertise, networks, and mentorship. HNWIs and angels seek opportunities that align with their risk appetite and strategic interests.

VERTICALS / 03

Investor Verticals We Work With

These are sophisticated entities such as banks, insurance firms, and pension funds, characterized by their substantial capital base and rigorous investment protocols. Institutional investors prioritize stable, long-term returns and typically engage in diversified investment portfolios.
Accredited retail investors are individuals who meet stringent financial criteria outlined by regulatory bodies. They possess the financial capacity to participate in private investment opportunities not accessible to the general public. Accredited retail investors pursue higher-yield prospects, often embracing a heightened risk tolerance.
HNWIs, distinguished by their considerable wealth, actively engage in direct investments, particularly in nascent ventures, as angel investors. Apart from financial backing, they offer valuable expertise, networks, and mentorship. HNWIs and angels seek opportunities that align with their risk appetite and strategic interests.

Book Your Call Today

Unlock Innovative Access to Global Capital with Direct Channels to Over 10 Million Institutional, Accredited Retail, and Angel Investors

@ 2024 Apex Ascension Inc. All Rights Reserved. 
1011, Earl Crescent, Burlington, Ontario, Canada